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The perceived global rise in chronic kidney disease (CKD) has
been met with apprehension and skepticism. It has been
argued by some that we are facing a CKD ‘epidemic’ and by
others that the high prevalence of CKD observed in different
communities may be the result of flawed screening methods
and tools. Both estimation of glomerular filtration rate and
determination of microalbuminuria as markers of CKD have
been criticized. Also, many commented that CKD, as currently
defined, was primarily a disease of elderly people with
reduced kidney function. Some described this as a
physiological age-related decline in kidney function while
others consider it to be pathological, warranting the label
of a disease. In this review, an attempt is made to reconcile
different views by examining some of the available evidence
and to conclude that the high prevalence of ‘CKD’ in the
elderly population is likely to reflect the underlying high
prevalence of overt and subclinical atherosclerosis and
cardiovascular disease. This leads to the conclusion that CKD
is a reflection of diffuse and age-related Cardio-Kidney-
Damage (C-K-D) that may not warrant the label of disease but
certainly justifies attention with reduction of lifelong
cardiovascular risks and careful evaluation and treatment.
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There is a widely held view that chronic kidney disease
(CKD) is common and that its prevalence is rising.1 The
global prevalence of chronic non-communicable disease is
also rising thus accounting for the worldwide increase in
cardiovascular deaths estimated globally at 25 million a year.2
It has long been argued that CKD impacts significantly on
cardiovascular disease (CVD) morbidity and mortality and
should therefore be a target for attention in its own right.
This mini review puts forward a unifying hypothesis
implying that the aging of the world population explains
the increased prevalence of both CVD and CKD; the latter
being a manifestation of the former.
CKD: CURRENT DEFINITION, PREVALENCE,
AND CONSEQUENCES
A number of explanations for the high prevalence of CKD
have been put forward, including hypertension, diabetes, and
the aging of the population. The high rates may also in part
be explained by the current definition and classification of
CKD and methods of detection. The current classification of
CKD (Kidney Disease Outcomes Quality Initiative 2002)
allows the labeling of CKD stages 1 and 2 (CKD1 and CKD2)
based on the sole presence of persistent microalbuminuria.3
This, on the assumption that microalbuminuria is a specific
sign of kidney damage. This definition and classification has
resulted in estimates of CKD prevalence in excess of 10% of
the population; 6–7% only having microalbuminuria.1,4
Estimates of CKD prevalence based on a low estimated
glomerular filtration rate (eGFR) (o60ml/min per 1.73m2)
tend to be around 3–5% of the population. Most tend to be
elderly individuals with reduced kidney function.
This has raised considerable concern in view of the
potential risks associated with CKD in terms of end-stage
renal disease but also the high cardiovascular morbidity and
mortality associated with albuminuria and/or reduced kidney
function regardless of age.4,5 Increasing awareness of CKD
has re-directed nephrology interest and resources toward
early detection and prevention of CKD.
CKD: THE CRITIQUE
Critics of this perceived rise in CKD argue that although there
may be a slight rise in CKD within the general population
associated with diabetes and hypertension, the prevalence of
CKD of around 10% is an overestimation.6 They argue that
the approaches and tools used to label individuals as suffering
from CKD are flawed and that the current definition and
classification of CKD have limitations.6
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First, microalbuminuria is not specific for CKD; it is a
marker of systemic inflammation and microvascular damage.
It is detected in a number of acute and chronic inflammatory
conditions, including dermatitis, gastritis, hepatitis as well as
arthritis and colitis. It is also observed in obesity, a condition
associated with systemic inflammation and endothelial
dysfunction. In some reports, it has been estimated that up
to 15% of obese individuals have microalbuminuria.7 Its
prevalence also rises with increased components of the
metabolic syndrome.8 Of note, in obese individuals micro-
albuminuria has been shown to be reversible on weight loss.9
Microalbuminuria is also associated with CVD reflecting
systemic capillary/endothelial damage, inflammation, and
increased permeability.10 It is therefore inappropriate to label
individuals as suffering from CKD on the sole presence of
microalbuminuria. Furthermore, many screening programs
have tested individuals only once without due reference to
the Kidney Disease Outcomes Quality Initiative guidelines
stipulating the persistence of albuminuria in two of three
urinary samples over a period of 3 months.3 Microalbumi-
nuria may be a marker of kidney/capillary damage, a
predictor of CVD in patients suffering from CKD but should
not be the sole definer of CKD. For that, other evidence of
specific and intrinsic renal damage such as hematuria or
reduced GFR should be present.
Second, the reliance on eGFR to detect a large number of
people with CKD may also be misleading. The most
commonly used formulas to calculate GFR, the Cockcroft
Gault and the Modification of Diet in Renal Disease (MDRD)
formulas, tend to underestimate kidney function, by as
much as 25–30%, in the upper range thus labeling a number
of individuals as suffering from CKD when their true GFR
is over 60ml/min per 1.73m2 (ref. 11). Furthermore, formula-
calculated GFR estimations are biased and inaccurate over
60ml/min per 1.73m2 (ref. 11). Consequently, many subjects
are labeled as suffering from CKD (mostly in stage 3a; GFR
between 60 and 45ml/min per 1.73m2) solely based on a
calculated and possibly inaccurate GFR estimation. As with
albuminuria, serum creatinine estimation in CKD population
screening programs is seldom repeated thus overlooking the
Kidney Disease Outcomes Quality Initiative classification
confirmatory requirements. Finally, most of the perceived
high prevalence of CKD is accounted for by individuals
over the age of 60 years.1,12 It has been argued that there is
a physiological decline in kidney function with age and
that labeling those as suffering from a CKD, in the
absence of associated albuminuria, is tendentious.6 Others
made the point that eGFR may not be the most appropriate
way for population screening for early CKD as the
majority of those detected are elderly people with reduced,
but stable GFR, who may not require or benefit from
interventions.13
CARDIO-KIDNEY-DAMAGE: A UNIFYING CONCEPT
The two sides of the above argument focus to a large extent
on the labeling and significance of CKD in the elderly. On the
one side a high CKD prevalence within the community with
inherent risks of end-stage renal disease and CVD and on the
other side an overestimation of the true scale of the problem
based on flawed detection methods and the assumption that
moderately reduced GFR (between 60 and 45ml/min per
1.73m2) in the elderly may be physiological and not
invariably harmful.
These views may overlook a number of facts leading to
such polarization. There is no doubt that CKD, as currently
defined and detected, mainly identifies older individuals with
microalbuminuria (CKD1 and CKD2) or reduced eGFR
(CKD3). But aging is associated with pathological rather
than physiological changes that may underlie and contribute
to microalbuminuria and a reduction in GFR. In fact, age-
related changes are primarily vascular and the kidney is
merely one of many affected target end organs along with the
brain and the heart.
The world population is aging.14,15 Over the last 50 years,
the proportion of those over the age of 60 years has risen
from 8 to 15% and is due to exceed 25% by 2050. By then,
more than 10% of the population will be over 80 years of age.
Increased age is associated with more disabilities including
hypertension and diabetes. In the United States, more than
50% of subjects over the age of 60 years suffer from
hypertension.16 Hypertension in the elderly is to a large
extent the cause as well as consequence of vascular aging
with atherosclerosis and the associated vascular stiffness.
Aging is also associated with increased prevalence of
diabetes mellitus, mainly type 2, with 20% of the US over-
60 population affected.17 Both hypertension and diabetes
are associated with vascular pathology. The kidneys are
particularly susceptible to age-related vascular injury and
damage.
In the elderly, microalbuminuria is associated with
vascular pathology: arterial and venous. Both atherosclerosis
and arterial stiffness are associated with increased urinary
albumin excretion.18,19 Also, microalbuminuria has been
shown to be associated with venous thromboembolism.20 In
fact, microalbuminuria is associated with clinical as well as
subclinical atherosclerosis and cardiovascular disease.21
Furthermore, atherosclerosis causing renal underperfusion
and ischemia in the elderly may also be directly implicated
in the pathogenesis of albuminuria as data have shown
an inverse relationship between renal perfusion and
albuminuria.22 Renal ischemia associated with age-related
atherosclerosis and endothelial dysfunction may therefore
explain the rising prevalence of microalbuminuria in the
elderly.7,23
The elderly often have reduced kidney function and GFR.
It has been estimated that from the age of 40–50 years onward
GFR falls by around 0.75 to 1ml/min per year.24 This is often
associated with histological changes suggestive of renal
vascular pathology, including arterial, arteriolar capillary,
and glomerular, sclerosis. However, it is becoming apparent
that not all individuals experience a decline in kidney
function with age and when it takes place loss of function
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varies in extent.24 Studies investigating the susceptibility to
CKD among the elderly have identified vascular pathology as
a major risk factor. A German study has identified
atherosclerosis, as estimated by increased carotid intima-
media thickness, as the predominant risk factor for incident
CKD.25 Studies from Japan26 and the United States27 showed
that elderly individuals with severe atherosclerotic peripheral
vascular disease may also be at increased risk. Thus, the
evidence implies that age-related decline in kidney function
may be the consequence, if not the by-product, of systemic
atherosclerosis causing progressive renal ischemia with
reduced GFR. In support of such concept, growing evidence
suggests that in elderly community-based individuals, the
long-term rate of decline of GFR is also independently
associated with the severity of atherosclerosis (carotid
intima-media thickness) and vascular/arterial stiffness (pulse
wave velocity).28 These observations suggest a role for
underlying atherosclerosis in the development and progres-
sion of CKD in the elderly.
The concept put forward in this review suggests that
individuals who are genetically predisposed and exposed
throughout their life course to CVD risk factors, including
hypertension and diabetes, develop age-related vascular
pathology with diffuse atherosclerosis affecting the kidneys.
Therefore, CKD as currently defined and detected in a
large percentage of the general population is the manifesta-
tion of age-related systemic vascular pathology and not a
primary disease or pathology confined to the kidneys. It is a
vascular syndrome that may be better described as Cardio-
Kidney-Damage (C-K-D) (Figure 1).
IMPLICATIONS OF C-K-D
C-K-D is clearly a consequence of modern lifestyles with
rising numbers of people suffering from hypertension,
obesity, and diabetes, many of whom smoke tobacco. The
impact of globalization and western lifestyles is now having
serious consequences on low- and middle-income econo-
mies, where all chronic noncommunicable diseases (hyper-
tension, obesity, diabetes, and CVD) are on the rise (WHO).
Consequently, the incidence of C-K-D is likely to rise in
emerging countries. By contrast, many high-income econo-
mies have addressed many of the CVD risk factors over the
last 25 years leading to a 70% reduction in CVD.2 Although
this may impact favorably on the incidence of C-K-D, the
increased lifespan in the West may counteract such benefit.
There is little doubt that C-K-D has major impact on
population health, morbidity, and mortality. Therefore,
much more needs to be worked out to reduce noncommu-
nicable disease underlying the growing incidence of C-K-D.
National and international initiatives are underway to
encourage a change in individuals’ lifestyle thus favoring
healthier dietary habits and more exercise. It is expected that
this will lead in the long term to a global reduction in the
burden of hypertension, obesity, diabetes, and smoking and
subsequently a healthier life course with a lower prevalence
of C-K-D.
National and international programs aimed at reducing
the burden of C-K-D should include screening for end-organ
damage including the kidneys by testing for albuminuria and
eGFR. These reflect the burden of vascular damage in a given
individual and therefore are likely to add to the prognostic
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Figure 1 | The Cardio-Kidney-Damage concept. Cardio-Kidney-Damage (C-K-D) concept that chronic kidney disease (CKD) in the
elderly is merely a manifestation of a broader age-related diffuse vascular damage affecting a number of end organs, including
the heart, kidneys, brain, and eyes among others.
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value of currently used CVD markers and scoring systems.
Such a screening when applied to those at risk in the
community (440–50 years; the age at which C-K-D is most
likely to start) may prove cost effective not only in terms of
end-stage renal disease prevention but also that of progressive
CVD. This has been the assumption behind the UK National
Vascular Strategy and campaign launched in 2009
(www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/
index.htm).
The C-K-D concept may also have therapeutic implications
including the focus on general population vascular protection,
which would invariably impact on the incidence of CKD in the
community. For individuals with established C-K-D, the advent
of the polypill may prove to be an effective tool in secondary
prevention by providing a cost-effective way of risk reduction.29
Of interest, some have also advocated the use of polypill in
aging individuals as a primary prevention strategy.30
More specifically, the distinction between C-K-D and
specific, and often overtly proteinuric, CKD secondary to
conditions such as chronic glomerulonephritis would
rationalize the use of agents such as inhibitors of the
renin–angiotensin system (RAS) that may be indicated and
beneficial in younger patients with primary proteinuric CKD,
but would be ineffective31 or even harmful32 in the elderly
with vascular and ischemic renal pathology. This would also
distinguish between CKD with proteinuria in young patients
with diabetic nephropathy where these agents are indicated
and of proven benefit and C-K-D in elderly people with
diabetes, hypertension, and diffuse atherosclerosis where
ischemic kidneys are at higher risk of severe dysfunction
when these agents are used. In the latter, discontinuation,
rather than initiation, of RAS inhibitors may prevent
progression to end-stage renal disease.33
CONCLUSION
The perceived global rise in CKD prevalence may be, to a large
extent, the result of the current definition and classification of
CKD that favors the detection of age-related renal abnorm-
alities including microalbuminuria and reduced GFR. These
reflect a wider systemic vascular pathology affecting the
kidneys of the elderly. C-K-D may prove to be a more suitable
label for many elderly individuals with atherosclerosis and
impaired kidney function whose overall prognosis depends to
a large extent on the severity of their underlying cardiovascular
disease (CVD). Albuminuria and reduction in GFR are simply
markers of the severity of the vascular disease. Describing these
individuals as having CKD, places an inappropriately selective
emphasis on the kidney. Describing them as suffering from C-
K-D may reflect a more accurate and broader perception of
this major health-care issue.
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